Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (43533)	3/24/2002 11:00:03 AM
From: LTK007	Read Replies (1) \| Respond to of 99280

the more i read this this is the kind of company i really like to short, this is a rotten company, and they are running out of dirty tricks.This is a dead stock in my view, dead dead dead. another goodie <<Schering-Plough is giving no ground. It has almost completely stopped promoting Claritin -- once the most heavily promoted drug in the world -- and launched a huge marketing campaign for Clarinex, aimed at both doctors and patients. Speaking to doctors, its sales representatives use words like "more potent," according to ImpactRx, a drug marketing research firm, even though there are no data showing that Clarinex is any better than Claritin. Schering-Plough has no comment. Claritin's share of the prescription-antihistamine market has eased off from its peak, to 34%. Clarinex, treated to the same kind of heavy promotion that Claritin once enjoyed, has managed in two months to capture 8%. Write to Gardiner Harris at gardiner.harris@wsj.com>>

To: LTK007 who wrote (43533)	3/24/2002 5:25:42 PM
From: Jdaasoc	Read Replies (1) \| Respond to of 99280

An FDA advisory committee began considering whether to switch Claritin and similar nonsedating antihistamines, such as Aventis SA's Allegra and Pfizer Inc.'s Zyrtec, to nonprescription status. Neighbor works for Scehering and was very clear that they decided that it was better to make Claritin an OTC drug before generics were made by competitors. I think Schering will decide to market it like premium brand like Bayer asprin and Tydenol. I asked her for the unpronounable generic name to see how it would sound after BJ's or Costco. I do not see a problem here maybe a advantage since there will be no insurance companies telling them how much they are willing to pay for it. She has 2 children in high school and wonders how she is going to pay for college and retirement with her 401K plan in tatters. Only bitch she has about company is that it is run by accountants not medical researchers.